(Q24235611)

title

Cannabinoid type 1 receptor antagonists for smoking cessation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6486173&resulttype=core&format=json

14 May 2020

0 references

0 references

0 references

1 reference

Kate Cahill

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6486173&resulttype=core&format=json

14 May 2020

Michael H Ussher

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6486173&resulttype=core&format=json

Cochrane Database of Systematic Reviews

14 May 2020

publication date

16 March 2011

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6486173&resulttype=core&format=json

14 May 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6486173&resulttype=core&format=json

14 May 2020

page(s)

CD005353

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6486173&resulttype=core&format=json

Rimonabant--a selective CB1 antagonist

14 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005353.PUB4

Randomized, controlled, double-blind trial of taranabant for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005353.PUB4

A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005353.PUB4

Trial comes too late as psychiatric side effects end hope for rimonabant

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005353.PUB4

Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005353.PUB4

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005353.PUB4

Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005353.PUB4

Rimonabant for overweight or obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005353.PUB4

Neuropharmacology and potential efficacy of new treatments for tobacco dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005353.PUB4

Smoking cessation and weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005353.PUB4

Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005353.PUB4

The need for dissemination of evidence-based results from research on nicotine and tobacco

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005353.PUB4

Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005353.PUB4

Early and late weight gain following smoking cessation in the Lung Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005353.PUB4

Short-term weight gain in abstaining women smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005353.PUB4

Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005353.PUB4

Body mass decrease after initial gain following smoking cessation

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21412887

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Measures of abstinence in clinical trials: issues and recommendations

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21412887

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Taranabant, a novel cannabinoid type 1 receptor inverse agonist.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21412887

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/14651858.CD005353.PUB4

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4126430

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6486173&resulttype=core&format=json

OpenCitations bibliographic resource ID

14 May 2020

4126430

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6486173&resulttype=core&format=json

14 May 2020

PubMed publication ID

21412887

1 reference